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Abstract
Over the last decade a better understanding of the
mechanism for immune disposal of hepatocytes infected with
the Hepatitis C virus enabled the design of antiviral regimens
with increasing efficacy.  The poor rates of sustained viral
clearance initially obtained with recombinant interferon (12%)
have now improved to over 70 % with the use of a combination
of pegylated interferon and the guanosine analogue ribavarine.
The relatively poor response of genotype 1 strains to this regimen
continues to challenge scientists and clinicians. This article
reviews the theoretical and practical aspects of selection of
patients for viral eradication, their management during
treatment and subsequent follow-up
Introduction
Hepatitis C Virus (HCV) is a highly evolved hepatotropic
virus that is capable of changing its genetic sequence during its
sojourn in the liver of an infected patient to form different
quasispecies.  This reduces recognition and clearance by the
host of virally infected cells leading to chronicity and eventual
liver fibrosis or cirrhosis.  The understanding of host-virus
interactions provided scientists with a framework for the design
of viral eradication regimens which have increased markedly
in efficacy during the last decade.  The physician needs to
combine this basic scientific knowledge with an understanding
of the armamentarium of drugs available for viral eradication.
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The philosophy behind anti-viral treatment:
know your aims
The ultimate objective of treatment is to reverse liver fibrosis
or halt its progression so as to minimise the risk of future liver
decompensation.  The standard aim of anti viral treatment is
absence of detectable HCV RNA by qualitative reverse
transcriptase polymerase chain reaction (PCR) at the end of
treatment and also at 24 weeks after the end of treatment  i.e. a
sustained viral response (SVR). The second NIH consensus
conference on the management of Hepatitis C1  reported that in
patients with SVR, liver biopsies taken 1-11 years after treatment
showed clear histological improvement in 89-100 per cent of
cases (3 studies) and a late recurrence of viraemia (detected by
qualitative PCR) in serum of  only 0-4%, while HCV was
undetectable by PCR in 400 liver biopsies 24 weeks after the
end of treatment in another study.
The antiviral armamentarium:
know how your weapons work
Interferons (alpha, beta and gamma) are glycoproteins
produced respectively by leukocytes, fibroblasts and lymphoid
cells. They are classified as negative growth factors since they
inhibit growth of a variety of cell types including those infected
by virus. Recombinant human interferon gamma had already
been used to treat chronic non-A, non-B hepatitis (NANB) a
few years before the discovery of HCV in 1989.2   Interferons
prevent viral entry and subsequent uncoating in the hepatocyte.
They activate ribonucleases and deactivate protein elongation
factors, degrading viral RNA and preventing its translation in
the cell.  They also amplify the response of natural killer cells
(NK cells) and cytotoxic T lymphocytes (CTL) to viral protein.
The relative  contribution of these modes of action to viral
eradication are not known. The ability of interferon to prevent
viral entry into healthy uninfected hepatocytes has been shown
to reduce the pool of circulating virus.  However a greater and
more sustained contribution to viral eradication stems from the
ability of interferon to accelerate immune detection and removal
of virally damaged hepatocytes.  The liver is probably the sole
site of replication of HCV as shown by the unique presence there
of messenger RNA and high hepatic levels of virus as compared
to serum.
In viraemic patients, typically less that one fifth of
hepatocytes contain HCV RNA and many of these display no
hepatocellular damage.  This would suggest  that HCV, though
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highly hepatotropic, shows minimal cytopathic activity in the
cells it infects.  Incomplete clearance of virally infected cells is
thought to result from an insufficient T cell response during
the acute phase or one that is ill-sustained. This sets the stage
for chronic inflammation and consequent fibrosis.
A poor initial immune response may be due to the fact that
hepatocytes are not professional antigen presenting cells.
Sustained viral clearance depends on presentation of adequate
amount of antigen to CD4+ (T-helper) lymphocytes in lymph
nodes as well as a Th1(T-helper l) cytokine response  which
promotes continuous and sustained activity of (CD8+) cytotoxic
lymphocytes in the liver. Sufficient and continuous production
of these cytokines is necessary to sustain the CTL response.  The
periodic administration of recombinant interferon boosts the
response and sustains removal of virally infected hepatocytes.
The kinetics of the viral pool has been extensively studied
during interferon therapy by serial measurements of circulating
HCV RNA concentrations.  The liver of viraemic patients
contains a large viral pool (108 – 1011 RNA copies/gm liver).3
Viral production (approximately 1012 virions per day) is balanced
by elimination into a virtual disposal compartment consisting
mostly of apoptotic or dead cells so that plasma levels are kept
relatively low (107 copies/ml plasma) which minimizes antigenic
stimulation.  Sustained clearance of viraemia (the previously
defined SVR) is typically associated with a greater than 2 log
drop in circulating HCV RNA  by 12 weeks of treatment and an
earlier normalisation of serum alanine aminotransferase  (ALT)
whereas smaller or slower drops in HCV RNA predict non-
response or a relapse within 24 weeks of stopping treatment.
Other predictors of a likely sustained response to interferon
treatment are genotype non-1, younger age, lower baseline body
weight or surface area and absence of bridging fibrosis on
baseline liver biopsy. Further studies will clarify whether the
poor response of genotype 1 HCV to interferon relates to greater
replicative capacity or resistance to Interferon.4  The original
regimen of standard interferon (IFN) 3MU thrice weekly (TIW)
for 24 weeks yielded SVRs of approximately 12% (2% in
genotype 1 and 16% in genotype non-1). Higher doses of IFN or
the use of daily “induction” dose IFN regimens unfortunately
produced a high drop out rate due to side effects. Prolonging
treatment to 48 weeks as recommended by the 1997 NIH
Consensus Conference on the management of hepatitis C raised
the overall SVR to 15-20%.
Therapeutic efficacy remained limited until the approval in
December 1998 of the therapeutic combination of subcutaneous
interferon and oral ribavarine (RBV) a guanosine (nucleoside)
analogue which is active against a number of viruses but which
was found to be ineffective when used as monotherapy against
HCV. FDA approval came shortly after McHutchinson et al
reported an SVR of 38% in patients treated with subcutaneous
IFN 3MU TIW and oral RBV 1000 or 1200mg daily for 48 weeks
compared to an SVR of 13% in patients who received IFN 3MU
TIW alone.5  Again, Genotype 1 patients had a lower SVR,
particularly when pre-treatment serum HCV RNA levels
exceeded 2x106 copies/ml. Subsequent trials 6 showed that
prolonging treatment with combination therapy beyond 24
weeks was unnecessary except in genotype 1 patients with serum
RNA > 2x106 copies/ml in whom prolonging treatment to 48
weeks  improved SVR from 17% to 29%. Genotype non-1 patients
had an SVR of 62% during 24 weeks of combination treatment
and the measurement of pre-treatment viral levels was not found
to be of practical importance in this group.
The slow decline of Genotype 1 viral levels in serum during
thrice weekly dosing with standard interferon may be due to
unduly low virocidal levels at the end of the dose interval.  The
half-life of standard interferon was lengthened from 6 hours to
90 hours by combination with a 40 kD branched molecule of
polyethylene glycol (PEG).  Pegylated Interferon (PEGIFN) with
an improved subcutaneous absorption and a reduced renal
clearance was licensed by the FDA in January  2001.
Fried et al7  compared a new combination of PEGIFN with
Ribavarine (PEGIFN+RBV) to PEGIFN alone and to the old
IFN+RBV combination. The results are shown in Table 1.
The data in genotype 1 patients show that PEGIFN alone
was found to be superior to the old IFN+RBV combinations
(SVR 21%) and further efficacy was obtained by combining
PEGIFN with RBV (SVR 46%) in 48 week regimens.  Side effects
necessitated dose reduction in some of the patients. Therefore
it is likely that lower doses may be equally efficacious.  It is also
likely that some may be treated successfully with a shorter period
of PEGIFN+RBV. Both these aspects are being studied further.
A number of putative  mechanisms for synergy between
interferons and RBV are also being looked into.
Pre treatment protocol:  prepare with care
Viraemic patients require a brief hospital admission for a
detailed history, examination, blood tests and a liver biopsy
during abdominal ultrasonography. Liver histology, genotype
analysis and baseline HCV RNA levels will allow a prediction of
sustained viral response to treatment which will guide the
Table 1: Sustained viral response (%) to three 48 week regimens
Treatment Regimen Overall Genotype 1* Genotype non 1
PEGIFN 180µg once weekly + Ribavarine 1000 or 1200mg daily x 48 weeks 56 46 (41*) 76
PEG IFN 180µg once weekly + placebo x 48 weeks 29 21 45
STD IFN 3MU thrice weekly + Ribavarine for 48 weeks 44 25 (33*) 61
* Genotype 1 patients with pre treatment HCV RNA > 106 copies/ml serum
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patient and physician to take a joint decision as to whether to
proceed with treatment.  Co-infection (e.g. CMV, HBV, HIV)
and co-existent autoimmune disease in the liver or other organs
should also be excluded.  Baseline full blood count, thyroid
function tests and blood glucose are also relevant (see below)
Selection of patients:  some hosts fight
the virus better better than others
Current minimal criteria for treatment include presence of
HCV RNA in serum, some degree of fibrosis or moderate
necroinflammation on liver biopsy, compensated liver disease,
abstinence from alcohol and intravenous drugs and acceptance
of treatment. Patients with genotypes 2 or 3 (especially those
with mild to moderate liver fibrosis on liver biopsy) should be
considered for immediate treatment with PEGIFN+RBV
because they are more likely to respond to treatment.  In patients
with genotypes I SVR is 40% or lower (see below).  In view of
the rapid rise in efficacy of anti viral regimens over the last four
years, genotype 1 patients may opt to wait for further
developments.8
 On the other hand patients aged over 40 and patients with
bridging fibrosis and/or high levels of serum HCV RNA ( all
predictors of a less favorable response to treatment) should be
advised that sustained response to currently available antiviral
treatment will drop as they grow older. Patients should also be
made aware that re-treatment with alternative regimens after
failure of regimens that contain interferon to eradicate the virus
may be less efficacious in interferon-failure patients than in
interferon-naïve patients.9 Patients with established cirrhosis
may be considered for treatment with PEGIFN+RBV unless
there are contraindications such as previous decompensation,
Childs-Pugh score >10 or cytopenias.10  Although some cirrhotic
patients  will achieve sustained viral clearance, for the majority,
the secondary end point (currently being studied in the HALT-
C trial)11  is a significant reduction in liver inflammation and
fibrosis that may be maintained by long-term treatment with
PEGIFN alone.  Patients with normal or near-normal ALT levels
respond to PEGIFN+RBV as well as patients with raised ALT.12
Selection of such patients for treatment should be based on other
factors such as genotypes, age and degree of liver fibrosis rather
than on ALT levels. Patients who did not respond during, or
relapsed after, IFN or IFN+RBV treatment should be considered
for PEGIFN+RBV treatment especially if there was previous
poor compliance to treatment which may be improved by
counseling and closer support. 14
Counselling pre-treatment:
preparing the host for attack
Patients who manage to take more than 80% of the total
dose of PEG IFN + RBV have improved SVR to treatment.14
Adherence can be maximised by adequate counselling and
follow up. Female patients and female sexual partners of male
patients should not become pregnant during and for six months
after the end of PEGIFN+RBV treatment.  Continued
Table 2: Side effects during PEG IFN + RBV treatment
Side effects Likely Cause Monitoring Action
Headaches, lassitude IFN
Fever, flu like symptoms IFN CBC Exclude cytopenia, infections
Mood changes IFN Psychiatric assessment Consider withdrawal of IFN + RBV
Transient ALT rise IFN Serial liver function tests Observe closely
Progressive ALT rise IFN INR, Bilirubin Discontinue treatment
Neutrophils < 750/mm3 IFN CBC Reduce IFN to 135µg/week
Neutrophils < 500/mm3 IFN CBC Suspend IFN until neutrophil
count exceeds  1000/cu mm then
restart at 90 µg/week
Platelet < 50,000/mm3 IFN CBC Reduce IFN to 90µg/week
Progressive thyroid dysfunction IFN TFT Reduce/suspend IFN
Anaemia, no cardiac disease RBV CBC Hb < 10g/dl, reduce RBV
to 600mg/daily
Hb < 8.5g/dl, suspend RBV
Anaemia, stable cardiac disease RBV CBC Hb drop > 2g/dl reduce RBV
to 600mg/day.  Hb < 12g/dl
despite 4 weeks at reduced dose:
discontinue RBV
Pulmonary Infiltrates IFN Chest X-Ray Discontinue IFN
Visual problems IFN Fundoscopy, Ischaemic retinal lesions,
check visual activity macular oedema, papilloedema:
stop IFN
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intravenous drug abuse,  depression, cytopenias, certain
anaemias (e.g. sickle cell anaemia), autoimmune disease (e.g.
of liver, thyroid and colon), uncontrolled diabetes and
decompensated liver disease are contraindications to treatment.
Coronary or cranial arterial diseases, renal impairment and
retinopathy and relative contraindications.  The manufacturer’s
recommendations for dosing and dose reduction should be
observed e.g. genotypes 1,4:  Pegasys® (Peg interferon alpha 2a)
180µgms s/c weekly with Copegus® (Ribavarine) 1000mg for
BW < 75kg, 1200 for BW > 75kg orally daily x 48 weeks;  for
genotypes 2,3: PegasysR 180 µg s/c weekly with Ribavarine
800mg orally daily x 24 weeks.
Treatment supervision:
maximising the offensive safely
Patients should be aware that certain complications may
necessitate dose reduction or withdrawal of treatment.  Besides
attending regular follow up and having blood tests, they should be
able to report significant side effects immediately  (see Table 2).
A favorable response to treatment is usually indicated by
an early fail in serum ALT.  Serum HCV RNA levels should be
checked after 12 weeks of treatment and compared to pre-
treatment levels. A drop of less then 2 log in viral load (copies
per ml) by quantitative PCR is highly predictive of failure to
achieve sustained viral clearance and is usually an indication to
stop treatment so as to limit costs and side effects.  Patients
who complete their treatment (24 or 48 weeks) should have
their serum re-tested by qualitative PCR in order to ensure that
there has been an end-of-treatment response.  HCV RNA is then
again checked 24 weeks after stopping treatment to ensure that
viral clearance is sustained. Periodic follow up will be necessary
to ensure continued absence of HCV RNA in the serum.
Conclusion: watch that space
During the last decade we have witnessed an impressive
improvement in the efficacy of anti-viral regimens for the
eradication of HCV. Research into antiretroviral therapy has
focused the search for more efficacious, better- tolerated drugs.
Novel subcutaneous albumin-linked and even oral
polyaminoacid-based interferons are on the horizon. Non-
haemolysing isomers or prodrug forms of ribavarine, inhibitors
of the NS3 protease component of the HCV polyprotein,
antisense molecules and ribozymes hold promise for increased
viral clearance especially in the difficult-to- treat genotype 1
disease.
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